ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 130

Anti-Ro/SSA Is Associated with Progression to End-Stage Renal Disease in Anti-dsDNA Positive Lupus Nephritis

Matthew Sherman1, Amali Gunawardana 2, Janine Amirault 2, Asha Moudgil 3, James Bost 3 and Hemalatha Srinivasalu 1, 1Children's National Medical Center, Washington, 2George Washington University, Washington, 3Children's Health Center, Children's National Medical Center, Washington

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: Antinuclear antibodies (ANA), juvenile SLE, Lupus nephritis

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Saturday, May 2, 2020

Title: Poster Session 3

Session Type: ACR Abstract Session

Session Time: 4:15PM-5:15PM

Background/Purpose: Lupus nephritis (LN) is related to disease severity, morbidity, and mortality in juvenile systemic lupus erythematosus (jSLE). Cluster analysis emerged to identify autoantibody profiles to better stratify disease phenotypes. Here, cluster analysis was performed to determine the existence of predictive autoantibody clusters in a cohort of biopsy-proven pediatric LN.

Methods: A retrospective chart review was performed of patients with jSLE found to have biopsy-confirmed LN at a quaternary pediatric hospital from 2007-2017. Primary endpoints: end-stage renal disease (ESRD) and mortality. K-medians clustering was performed, and patients with a complete autoantibody profile (ANA, anti-dsDNA, anti-Smith, anti-RNP, anti-Ro/SSA, anti-La/SSB) were included. Chi-square test was used for categorical variables. Kruskal-Wallis test was used for continuous measures. Significance was set at p< 0.05.

Results: Fifty-three patients met inclusion criteria. Demographics are listed in Table 1. Forty-nine (92.5%) fulfilled ACR and all (100%) fulfilled SLICC criteria based on biopsy-proven LN. jSLE manifestations are listed in Table 2. Most presented with LN within 1 year of jSLE (n=43, 81.1%), and LN was commonly the initial presentation (n=29, 54.7%). LN class V was most frequent (n=31, 58.5%) followed by class IV (n=28, 52.8%), class II (n=13, 24.5%), and class III (n=9, 17%). Twenty-two of those with LN class V and 3 of those with class IV were also positive for another class. Six progressed to ESRD. No mortalities were reported. ANA was positive in 94.3% of patients, of which 29 had titer >1:1280 (58%). Other autoantibody frequencies included: anti-dsDNA 96.2%, anti-RNP 67.9%, anti-Smith 66%, anti-Ro/SSA 62.3%, anti-La/SSB 26.4%. Forty-six had a complete autoantibody profile, including 4 with ESRD. Three distinct clusters were identified (Table 3). Anti-dsDNA was positive in all but one (97.8%). Group 1 was distinct by negative anti-Ro/SSA and anti-La/SSB; group 2 by predominantly high titer ANA ( >1:1280) and nearly all positive anti-Smith and anti-RNP; and group 3 by more commonly negative anti-Smith and anti-RNP and all positive anti-Ro/SSA. There was no significant difference in the distribution of sex, race, or jSLE manifestations. There was a significant difference in the distribution of LN class IV (p=0.016), with the highest percentage in group 1 (n=8, 100%) followed by group 3 (n=5, 50%) and group 2 (n=12, 42.9%). Those in group 3, significantly, were younger at diagnosis of jSLE (p=0.026) and LN (p=0.013), had higher creatinine (p=0.030) at LN diagnosis, and were more likely to progress to ESRD (p=0.025). All but 1 patient with ESRD was in cluster 3.

Conclusion: Cluster analysis revealed that in anti-dsDNA positive LN, the presence of anti-Ro/SSA is associated with earlier decline in renal function and increased risk for ESRD.

Demographics

jSLE Manifestations

Autoantibody Clusters


Disclosure: M. Sherman, None; A. Gunawardana, None; J. Amirault, None; A. Moudgil, None; J. Bost, None; H. Srinivasalu, None.

To cite this abstract in AMA style:

Sherman M, Gunawardana A, Amirault J, Moudgil A, Bost J, Srinivasalu H. Anti-Ro/SSA Is Associated with Progression to End-Stage Renal Disease in Anti-dsDNA Positive Lupus Nephritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/anti-ro-ssa-is-associated-with-progression-to-end-stage-renal-disease-in-anti-dsdna-positive-lupus-nephritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-ro-ssa-is-associated-with-progression-to-end-stage-renal-disease-in-anti-dsdna-positive-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology